Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography the multi-ethnic study of atherosclerosis lung study

Annals of the American Thoracic Society

Volumn 14, Issue 5, 2017, Pages 649-658

  Parikh, Megha A ^a   Aaron, Carrie P ^a   Hoffman, Eric A ^b   Schwartz, Joseph E ^a,c   Madrigano, Jaime ^d   Austin, John H M ^a   Kalhan, Ravi ^e   Lovasi, Gina ^d   Watson, Karol ^f   Stukovsky, Karen Hinckley ^g   Barr, R Graham ^a,d  

^a PH 9 East ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Department of Medicine   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Emphysema; Lung; Pharmacoepidemiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; EMPHYSEMA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; LOW DRUG DOSE; LUNG FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SMOKING; SPIROMETRY; STATISTICAL ANALYSIS; X-RAY COMPUTED TOMOGRAPHY; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLICATION; DIAGNOSTIC IMAGING; LUNG EMPHYSEMA; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; SMOKING; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85018994722     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201604-317OC     Document Type: Article

References (57)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. Vestbo J, Hurd SS, AgustíAG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
3. Drummond MB, Buist AS, Crapo JD, Wise RA, Rennard SI. Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11(Suppl 3):S154-S160.
4. Auerbach O, Hammond EC, Garfinkel L, Benante C. Relation of smoking and age to emphysema-whole-lung section study. N Engl J Med 1972;286:853-857.
5. Smith BM, Austin JH, Newell JD Jr, D'Souza BM, Rozenshtein A, Hoffman EA, Ahmed F, Barr RG. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study. Am J Med 2014;127:94.e7-94.e23.
6. Johannessen A, Skorge TD, Bottai M, Grydeland TB, Nilsen RM, Coxson H, Dirksen A, Omenaas E, Gulsvik A, Bakke P. Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med 2013;187:602-608.
7. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, Hirai T, Niimi A, Nishimura K, Chin K, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010;138:635-640.
8. McAllister DA, Ahmed FS, Austin JH, Henschke CI, Keller BM, Lemeshow A, Reeves AP, Mesia-Vela S, Pearson GD, Shiau MC, et al. Emphysema predicts hospitalisation and incident airflow obstruction among older smokers: a prospective cohort study. PLoS One 2014;9:e93221.
9. Oelsner EC, Lima JA, Kawut SM, Burkart KM, Enright PL, Ahmed FS, Barr RG. Noninvasive tests for the diagnostic evaluation of dyspnea among outpatients: the Multi-Ethnic Study of Atherosclerosis lung study. Am J Med 2015;128:171-180.e5.
10. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright PL, Kawut SM, Kronmal R, Lederer D, Lima JA, Lovasi GS, et al. Association between emphysema-like lung on cardiac computed tomography and mortality in persons without airflow obstruction: a cohort study. Ann Intern Med 2014;161:863-873.
11. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe a1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360-368.
12. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampfli M, Lavery C, Margetts PJ, Roberts AB, Gauldie J. Smad3 null mice develop airspace enlargement and are resistant to TGF-betamediated pulmonary fibrosis. J Immunol 2004;173:2099-2108.
13. Chen H, Sun J, Buckley S, Chen C, Warburton D, Wang XF, Shi W. Abnormal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema. Am J Physiol Lung Cell Mol Physiol 2005;288:L683-L691.
14. Pavel J, Terron JA, Benicky J, Falcon-Neri A, Rachakonda A, Inagami T, Saavedra JM. Increased angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice. Regul Pept 2009;158:156-166.
15. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ, Laurent GJ. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L156-L164.
16. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195-202.
17. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, KuT, LauerT, McGrath-MorrowS, BergerA, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest 2012;122:229-240.
18. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Boger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-371.
19. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, LuscherTF, Klibaner MI, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265. [Published erratum appears in Circulation 1996;94:1490.]
20. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005;11:491-498.
21. Barr RG, Mesia-Vela S, Austin JH, Basner RC, Keller BM, Reeves AP, Shimbo D, Stevenson L. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 2007;176:1200-1207.
22. Lambert A, Neptune E, Brown R, Diette G, Drummond M, Hansel N, Liu M, Shade D, Wise R. Angiotensin receptor blockade treatment for COPD: phase II trial [abstract]. Chest 2015;148:744A.
23. Parikh MA, Hoffman EA, Schwartz J, Madrigano J, Austin J H M, Lovasi GS, Watson K, Stukovsky KH, Barr RG, Kalhan R. Angiotensin II receptor blockers, ACE inhibitors and longitudinal change in percent emphysema: the MESA Lung Study [abstract]. Am J Respir Crit Care Med 2013;187:A2425.
24. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-881.
25. Kaufman JD, Adar SD, Allen RW, Barr RG, Budoff MJ, Burke GL, Casillas AM, Cohen MA, Curl CL, Daviglus ML, et al. Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol 2012;176:825-837.
26. Rodriguez J, Jiang R, Johnson WC, MacKenzie BA, Smith LJ, Barr RG. The association of pipe and cigar use with cotinine levels, lung function, and airflow obstruction: a cross-sectional study. Ann Intern Med 2010;152:201-210.
27. Smith NL, Psaty BM, Heckbert SR, Tracy RP, Cornell ES. The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol 1999;52:143-146.
28. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005;234:35-43.
29. Couper D, LaVange LM, Han M, Barr RG, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG, et al.; SPIROMICS Research Group. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 2014;69:491-494.
30. Zhang L, Hoffman EA, Reinhardt JM. Atlas-driven lung lobe segmentation in volumetric X-ray CT images. IEEE Trans Med Imaging 2006;25:1-16.
31. Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault JC. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996;154:187-192.
32. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomographic lung densitometry for monitoring emphysema in a1-antitrypsin deficiency. Thorax 2006;61:485-490.
33. Barr RG, Ahmed FS, Carr JJ, Hoffman EA, Jiang R, Kawut SM, Watson K. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J 2012;39:846-854.
34. Hoffman EA, Jiang R, Baumhauer H, Brooks MA, Carr JJ, Detrano R, Reinhardt J, Rodriguez J, Stukovsky K, Wong ND, et al. Reproducibility and validity of lung density measures from cardiac CT scans-the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Acad Radiol 2009;16:689-699.
35. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
36. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Chest 2010;137:138-145.
37. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-1060.
38. Ogburn EL, Rotnitzky A, Robins JM. Doubly robust estimation of the local average treatment effect curve. J R Stat Soc Series B Stat Methodol 2015;77:373-396.
39. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45(10 Suppl 2):S103-S107.
40. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45.
41. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2560.
42. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001;163:1476-1483.
43. Vignola AM, Chanez P, Chiappara G, Merendino A, Zinnanti E, Bousquet J, Bellia V, Bonsignore G. Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases. Clin Exp Immunol 1996;106:114-119.
44. Hersh CP, Hansel NN, Barnes KC, Lomas DA, Pillai SG, Coxson HO, Mathias RA, Rafaels NM, Wise RA, Connett JE, et al.; ICGN Investigators. Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema. Am J Respir Cell Mol Biol 2009;41:324-331.
45. Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, Fujimoto K, Ota M. The association of transforming growth factor beta 1 gene polymorphisms with the emphysema phenotype of COPD in Japanese. Intern Med 2008;47:1387-1394.
46. Funada Y, Nishimura Y, Yokoyama M. Imbalance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 is associated with pulmonary emphysema in Klotho mice. Kobe J Med Sci 2004;50:59-67.
47. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
48. Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stromainfiltrating myeloid cells. ScientificWorldJournal 2014;2014:521754.
49. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-581.
50. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
51. Hueper K, Vogel-Claussen J, Parikh MA, Austin JH, Bluemke DA, Carr J, Choi J, Goldstein TA, Gomes AS, Hoffman EA, et al. Pulmonary microvascular blood flow in mild chronic obstructive pulmonary disease and emphysema: the MESA COPD Study. Am J Respir Crit Care Med 2015;192:570-580.
52. Mohamed Hoesein FA, Zanen P, de Jong PA, van Ginneken B, Boezen HM, Groen HJ, Oudkerk M, de Koning HJ, Postma DS, Lammers JW. Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study. Respir Res 2013;14:55.
53. PetersenH, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensinconverting enzyme inhibitor use. Chest 2014;145:695-703.
54. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013;1:129-136.
55. Manichaikul A, Hoffman EA, Smolonska J, Gao W, Cho MH, Baumhauer H, Budoff M, Austin JH, Washko GR, Carr JJ, et al. Genome-wide study of percent emphysema on computed tomography in the general population: the Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med 2014;189:408-418.
56. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007;176:742-747.
57. Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, et al.; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-tosevere COPD. N Engl J Med 2014;370:2201-2210.